By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

The pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

Pharmaceutical giant AstraZeneca is suing Utah’s attorney general and insurance commissioner over a law passed during the ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing ...